Wilmer Cutler Pickering Hale and Dorr represented Agios Pharmaceuticals, Inc. in the deal. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation...
Agios Pharmaceutical’s $905 Million Purchase Agreement for Vorasidenib Royalty
Gilead Sciences’ $647.5 Million License Agreement with Xilio Therapeutics
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...
Infinity Pharmaceuticals’ Merger with MEI Pharma
Wilmer Cutler Pickering Hale and Dorr advised Infinity Pharmaceuticals on the deal, while Morgan Lewis represented MEI Pharma Inc. Infinity Pharmaceuticals and MEI Pharma announced that...
Volastra Therapeutics’ $60M Series A Financing
WilmerHale represented Volastra Therapeutics on the deal. Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), closed its $60 million Series...
LG Chem’s Acquisition of AVEO Oncology
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...
Volastra Therapeutics’ Extended $44M Seed Financing
Wilmer Cutler Pickering Hale and Dorr LLP advised Volastra Therapeutics on the deal. Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment...